Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Globe Newswire•21/10/2026•08:00 ET
0
Key Highlights
- ➤Sutro dosed the first patient in STRO-006’s Phase 1 solid-tumor trial
- ➤STRO-006 is Sutro’s second wholly owned ADC entering clinical testing within one year
- ➤Initial clinical data from STRO-006 are expected in the second half of 2027
- ➤Phase 1 dose escalation begins at 1.5 mg/kg across ITGB6-expressing solid tumors
Expert Statements
Jane Chung, Chief Executive Officer of Sutro Biopharma
“Dosing the first patient with STRO-006 marks our second ADC to enter the clinic in less than a year and reflects the Sutro team’s exceptional execution of our pipeline strategy.”
Jane Chung, Chief Executive Officer of Sutro Biopharma
“ITGB6 is difficult to target due to complex biology and is expressed across a broad range of tumors with high unmet need, including non-small cell lung and head and neck cancers.”
Jane Chung, Chief Executive Officer of Sutro Biopharma
“In preclinical models, STRO-006 demonstrated potent, sustained anti-tumor activity with minimal on-target toxicity, supporting our belief that Sutro’s advanced design capabilities can widen the therapeutic index and deliver a differentiated safety and efficacy profile.”
Jane Chung, Chief Executive Officer of Sutro Biopharma
“We look forward to advancing STRO-006 in the clinic and evaluating its potential to benefit patients.”
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —
— Initial clinical data expected in the second half of 2027 —
Get started
Create a free account to read the full story.